Top

Published in:

Open Access 01-01-2019 | Original Article

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer

Authors: Hironori Fujii, Yunami Yamada, Daichi Watanabe, Nobuhisa Matsuhashi, Takao Takahashi, Kazuhiro Yoshida, Akio Suzuki

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2019

Abstract

Purpose

Irinotecan is effective for metastatic colorectal cancer (mCRC). SN-38 is an active metabolite of irinotecan, which is formed by carboxylesterase and inactivated by UDP-glucuronyltransferase (UGT) 1A1. The UGT enzyme activity is reduced in patients with homozygous mutation in UGT1A1 genes (*6/*6, *28/*28 and *6/*28); thus dose reduction is required for prevention of severe adverse events associated with irinotecan. The present study was designed to investigate the relationship between UGT1A1 polymorphisms and the incidence of adverse events or the therapeutic effect in mCRC patients who received irinotecan.

Methods

Sixty-three mCRC patients who received irinotecan during January 2014 and May 2018 were the subjects of this study. The incidence of adverse events, including diarrhea and neutropenia, and the therapeutic effect of irinotecan were compared among homozygous group, heterozygous group and wild-type group. The initial dose of irinotecan was 150 mg/m² in the heterozygous group and wild-type group, while the dose was reduced by 20% (120 mg/m²) in the homozygous group.

Results

The UGT1A1 polymorphisms occurred in 15.9%, 33.3%, and 50.8% for homozygous group, heterozygous group, and wild-type group, respectively. The average dose of irinotecan during overall cycles was not significantly different among three groups, despite the reduction of initial dose in homozygous group. There were no significant differences in the incidence rates of adverse events, tumor response, or time to treatment failure among three groups.

Conclusion

The present study demonstrated that dose reduction by 20% ensured safety and efficacy of irinotecan in mCRC patients with homozygous mutation in UGT1A1 genes.

Shimada Y, Yoshino M, Wakui A et al (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11:909–913. https://doi.org/10.1200/JCO.1993.11.5.909 CrossRefPubMed

Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047. https://doi.org/10.1016/S0140-6736(00)02034-1 CrossRefPubMed

Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237. https://doi.org/10.1200/JCO.2004.05.113 CrossRefPubMed

Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786. https://doi.org/10.1200/JCO.2007.15.5390 CrossRefPubMed

Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27:1539–1546. https://doi.org/10.1093/annonc/mdw206 CrossRefPubMed

Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. https://doi.org/10.1056/NEJMoa0805019 CrossRefPubMed

Köhne CH, Hofheinz R, Mineur L et al (2012) First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138:65–72. https://doi.org/10.1007/s00432-011-1061-6 CrossRefPubMed

Kono A, Hara Y (1991) Conversion of CPT-11 into SN-38 in human tissues. Gan To Kagaku Ryoho 18:2175–2178PubMed

Kawato Y, Aonuma M, Matsumoto K (1991) Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities. Gan To Kagaku Ryoho 6:899–907. https://doi.org/10.2133/dmpk.6.899 CrossRef

10.

Rivory LP, Robert J (1995) Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176–179. https://doi.org/10.1007/BF00689205 CrossRefPubMed

11.

Haaz MC, Rivory L, Jantet S et al (1997) Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 80:91–96. https://doi.org/10.1111/j.1600-0773.1997.tb00289.x CrossRefPubMed

12.

Iyer L, Hall D, Das S et al (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576–582. https://doi.org/10.1016/S0009-9236(99)70078-0 CrossRefPubMed

13.

Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926. https://doi.org/10.1097/00007691-200202000-00018 CrossRefPubMed

14.

Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497–504. https://doi.org/10.1097/FPC.0b013e328014341f CrossRef

15.

Sai K, Sawada J, Minami H (2008) Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28. Yakugaku Zasshi 128:575–584. https://doi.org/10.1248/yakushi.128.575 CrossRefPubMed

16.

Satoh T, Ura T, Yamada Y et al (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868–1873. https://doi.org/10.1111/j.1349-7006.2011.02030.x CrossRefPubMed

17.

Miyata Y, Touyama T, Kusumi T et al (2016) UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol 21:696–703. https://doi.org/10.1007/s10147-015-0937-x CrossRefPubMed

18.

Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388. https://doi.org/10.1200/JCO.2004.07.173 CrossRefPubMed

19.

Package insert, CAMPTO® (Irinotecan Hydrochloride Hydrate) for I.V. infusion (2011) 14th edn. Yakult Honsha Co., Ltd

20.

Package insert, Camptosar® (Irinotecan hydrochloride) Injection (2011) Pfizer Inc.

21.

US Department of Health and Human Services, National Institutes of Health National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) version 4.0. https://www.eortc.be/services/doc/ctc/

22.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

23.

Raijmakers MT, Jansen PL, Steegers EA et al (2000) Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33:348–351. https://doi.org/10.1016/S0168-8278(00)80268-8 CrossRefPubMed

24.

Borlak J, Thum T, Landt O et al (2000) Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert’s syndrome) in healthy subjects. Hepatology 32:792–795. https://doi.org/10.1053/jhep.2000.18193 CrossRefPubMed

25.

Chang JL, Bigler J, Schwarz Y et al (2007) UGT1A1 polymorphism is associated with serum bilirubin concentrations in a randomized, controlled, fruit and vegetable feeding trial. J Nutr 137:890–897. https://doi.org/10.1093/jn/137.4.890 CrossRefPubMed

26.

Chen Z, Su D, Ai L et al (2014) UGT1A1 sequence variants associated with risk of adult hyperbilirubinemia: a quantitative analysis. Gene 552:32–38. https://doi.org/10.1016/j.gene.2014.09.009 CrossRefPubMed

Title: Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
Authors: Hironori Fujii
Yunami Yamada
Daichi Watanabe
Nobuhisa Matsuhashi
Takao Takahashi
Kazuhiro Yoshida
Akio Suzuki
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3711-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis

Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA)

Correction to: Aromatase inhibitor-induced carpal tunnel syndrome: prevalence in daily practice

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics

Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer